Effects of quercetin and arginine on the nephrotoxicity and lipid peroxidation induced by gold nanoparticles in vivo
Authors Abdelhalim MAK, Qaid HAY, Al-Mohy Y, Al-Ayed MS
Received 9 August 2018
Accepted for publication 3 October 2018
Published 21 November 2018 Volume 2018:13 Pages 7765—7770
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Govarthanan Muthusamy
Peer reviewer comments 2
Editor who approved publication: Dr Thomas J Webster
Mohamed Anwar K Abdelhalim, Huda AY Qaid, Yanallah Al-Mohy, Mohammed Suliman Al-Ayed
Department of Physics and Astronomy, College of Science, King Saud University, Riyadh, Saudi Arabia
Introduction: This study aimed to evaluate the nephrotoxicity caused by gold nanoparticles (GNPs) and investigate the potential roles of quercetin (Qur) and arginine (Arg) in mitigating the inflammatory kidney damage and dysfunction and inhibiting the toxicity induced by GNPs in rats.
Methods: Kidney function was assessed using various serum biomarkers, including blood urea nitrogen (BUN), uric acid (URIC), and creatinine (CR), while toxicity was evaluated by measuring the biomarkers glutathione (GSH) and malondialdehyde (MDA) in kidney tissues.
Results: Administration of GNPs to the rats severely affected the serum kidney biomarkers, as confirmed by the notable increases in BUN, URIC, and CR. Substantial changes in the levels of the biomarkers MDA and GSH in the kidney tissues were also observed, with a reduced level of GSH and elevated MDA activity. The administration of Qur or Arg exerted a protective effect against GNP-induced inflammatory kidney damage and toxicity, but with different responses according to their evaluated normalized values.
Conclusion: This study demonstrates the beneficial effects of supplementation with Qur or Arg during the treatment with GNPs, potentially providing a powerful tool for cancer therapy.
Keywords: gold nanoparticles, nephrotoxicity, lipid peroxidation, inflammatory damage, natural antioxidants
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]